Search company, investor...
Search

Predict your next investment

National Center For Advancing Translational Sciences company logo
Government
HEALTHCARE | Medical Information
ncats.nih.gov

See what CB Insights has to offer

Investments

16

Portfolio Exits

1

Partners & Customers

10

About National Center For Advancing Translational Sciences

National Center for Advancing Translational Sciences (NCATS) is one of 27 Institutes and Centers at the National Institutes of Health (NIH) and was established to transform the translational process so that new treatments and cures for disease can be delivered to patients faster.

National Center For Advancing Translational Sciences Headquarters Location

6701 Democracy Blvd 9th and 10th Floors

Bethesda, Maryland, 20892,

United States

301-594-8966

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

National Center For Advancing Translational Sciences Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

National Center For Advancing Translational Sciences Rank

Latest National Center For Advancing Translational Sciences News

UCLA receives Clinical and Translational Science Award from the National Center for Advancing Translational Sciences

Jul 15, 2022

UCLA has received a $59 million Clinical and Translational Science Award from the National Center for Advancing Translational Sciences (NCATS). The five-year award supports the UCLA Clinical and Translational Science Institute (CTSI), a research partnership among UCLA, Charles Drew University of Medicine and Science, the Lundquist Institute at Harbor-UCLA Medical Center, and Cedars-Sinai Medical Center. This is the second renewal for UCLA after receiving its first award in 2011. The CTSI is led by Drs. The UCLA CTSI is among the largest institutes of a 60-member consortium established by NCATS to accelerate the translation of scientific discoveries into effective health interventions that improve clinical care. The intent of the consortium is to harness the strengths of its members in achieving greater health impact than a single institution can achieve on its own. “This continued funding will help us expand our efforts to translate discoveries that can improve the of health of Los Angeles County’s diverse population,” said Dr. John Mazziotta, vice chancellor of UCLA Health Sciences and CEO of UCLA Health. “Working with our partners, we can continue to build the capability of scientists, healthcare, and public health systems to integrate research and clinical care to solve the most pressing population health problems. I would also like to thank and congratulate all the many members of our organization who contributed to the success of this grant and to the CTSI leadership who have consistently pursued our missions and our values.” The UCLA CTSI was instrumental in the rapid research response to the COVID-19 pandemic, supporting more than 200 basic, clinical and translational studies at UCLA and its partner institutions. This response included a UCLA CTSI-led statewide collaborative effort across 11 academic institutions and more than 75 community partners to increase vaccination rates and participation in clinical trials for at-risk populations. This academic-community collaborative in Los Angeles County increased the participation of underrepresented groups in four vaccine trials to greater than 65%. The collaborative was supported in part by a grant from the NIH Community Engagement Alliance (CEAL). The UCLA CTSI has focused from its inception on improving health and health care delivery in Los Angeles County, prioritizing populations experiencing health disparities. Research conducted with the Los Angeles County Department of Health Services in the county’s health care system led to significantly higher screening rates for diabetic retinopathy, the leading cause of preventable blindness in adults. In collaboration with community pharmacists and 52 Black-owned barbershops, the UCLA CTSI demonstrated a successful model for detecting and treating undiagnosed high-blood pressure in barbershop patrons. “Based on the firm CTSI foundation developed in the past decade, we are now poised to accelerate the impact for the health of all of our communities”, said Dr. Dubinett, founding CTSI director and Interim Dean, David Geffen School of Medicine at UCLA. The UCLA CTSI has supported more than 2,100 investigators at its four partner institutions. This support contributed to important discoveries, which included discoveries in lung cancer and breast cancer, two of the leading causes of premature death and disability in Los Angeles County. Through its extensive training and education programs, the UCLA CTSI has been preparing the next generation of clinical and translational scientists. During its first decade, the UCLA CTSI trained more than 1,080 junior faculty, postdoctoral scholars, graduate and healthcare professional students, undergraduates and research staff. The UCLA CTSI annually has supported 10,000 clinical research visits in outpatient, inpatient and community settings; created the Los Angeles Data Resource, a federation of clinical data warehouses encompassing UCLA, the University of Southern California, Children’s Hospital Los Angeles, City of Hope and Cedars-Sinai; supported the creation of a precision health biobank, powered by an innovative, universal video informed consent process; and formed a research partnership with Los Angeles County that has affected both the care provided by more than 270 physicians and the outcomes of more than 80,000 patients in the county health system. Additional accomplishments include creating the CTSI Center for Systematic, Measurable, Actionable, Resilient, and Technology-driven (SMART) Health, which develops digital and data-driven health care technologies, and the CTSI Office of Clinical Research, which develops more effective ways to speed the activation of clinical trials. “The importance of addressing and eliminating health disparities is abundantly clear. Diverse health science research leads to equitable health outcomes and plays a key role in tackling pressing medical and well-being challenges in all communities. Our dynamic partnership of four institutions has remained unswervingly focused on this pursuit of health equity through research, and this renewed support from NIH will allow us to continue unabated for another half-decade,” said Dr. David Carlisle, president and chief executive of Charles R. Drew University of Medicine and Science. “For more than seven decades, innovations at The Lundquist Institute for Biomedical Innovation have placed essential and life-saving tools in the hands of physicians and health care workers,” said Dr. David Meyer, president and chief executive of the Lundquist Institute. “Through the CTSI partnership and the benefits that it brings to the Lundquist, we will be able to ensure that future discoveries continue to improve the health of our diverse community.” “This award advances our comprehensive translational research programs dedicated to enabling scientific discoveries for the direct benefit to our patients and the community,” said Dr. Shlomo Melmed, executive vice president and dean of the medical faculty at Cedars–Sinai. “As the largest academic medical center in California, Cedars-Sinai is pleased to partner with our UCLA colleagues in this multidisciplinary endeavor to improve the health of our community and enhance our diagnosis and treatment of disease.” In the next five years, the UCLA CTSI will build on its progress by broadening collaborations with the community as well as with faculty across a wide area of expertise, including engineering, business and public health. The CTSI also plans to establish mobile units to bring clinical trials to underserved communities; enhance training and education programs with team science principles; and apply its expertise in data science and artificial intelligence to improve health care delivery. The UCLA CTSI has embarked on an Inclusive Science Initiative that emphasizes diversity, equity and inclusion in research activities as well as in research training. The Inclusive Science Initiative is led by Dr. Keith Norris, UCLA CTSI senior associate director and professor of medicine at UCLA. “The CTSI fosters an environment where we are able to expand our capacity for collaboration, community engagement, and team science that captures the imagination of our researchers and community,” said Dr. Naeim, who is also chief medical officer for clinical research for UCLA Health. “That’s what makes the work of the CTSI so compelling.”

National Center For Advancing Translational Sciences Investments

16 Investments

National Center For Advancing Translational Sciences has made 16 investments. Their latest investment was in Weill Cornell Medicine as part of their Grant - III on September 9, 2022.

CBI Logo

National Center For Advancing Translational Sciences Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

9/9/2022

Grant - III

Weill Cornell Medicine

$61.9M

No

3

7/26/2022

Grant

STRM.BIO

$2.1M

Yes

1

5/12/2022

Grant - III

Sound Pharmaceuticals

$1.1M

No

1

4/6/2021

Grant - II

Subscribe to see more

$99M

Subscribe to see more

10

8/21/2020

Grant - II

Subscribe to see more

$99M

Subscribe to see more

10

Date

9/9/2022

7/26/2022

5/12/2022

4/6/2021

8/21/2020

Round

Grant - III

Grant

Grant - III

Grant - II

Grant - II

Company

Weill Cornell Medicine

STRM.BIO

Sound Pharmaceuticals

Subscribe to see more

Subscribe to see more

Amount

$61.9M

$2.1M

$1.1M

$99M

$99M

New?

No

Yes

No

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

3

1

1

10

10

National Center For Advancing Translational Sciences Portfolio Exits

1 Portfolio Exit

National Center For Advancing Translational Sciences has 1 portfolio exit. Their latest portfolio exit was Recursion on April 16, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

4/16/2021

IPO

$99M

Public

23

Date

4/16/2021

Exit

IPO

Companies

Valuation

$99M

Acquirer

Public

Sources

23

National Center For Advancing Translational Sciences Partners & Customers

10 Partners and customers

National Center For Advancing Translational Sciences has 10 strategic partners and customers. National Center For Advancing Translational Sciences recently partnered with Virpax Pharmaceuticals on November 11, 2021.

Date

Type

Business Partner

Country

News Snippet

Sources

11/10/2021

Vendor

United States

Virpax Advances Envelta™ Development with NCATS Under CRADA Agreement

IND-enabling studies for Envelta are being performed under a Cooperative Research and Development Agreement with NCATS entered into by Virpax Pharmaceuticals in August of 2020 .

1

5/25/2021

Partner

United States

08:38 ET BurstIQ and The National Center for Advancing Translational Sciences (NCATS) At The National Institutes of Health (NIH)...

To learn more about BurstIQ 's collaboration with National Center for Advancing Translational Sciences and how the companies are working together to drive collaborative research , please contact us at -LSB- email protected -RSB- .

1

4/12/2021

Partner

United States

(Parth Desai, M.D., National Cancer Institute). National Center for Advancing Translational Sciences Drug Testing Approach Uncovers Effective Combination for Treating Small Cell Lung Cancer.

Scientists at NIH 's National Cancer Institute and NCATS teamed up to find another option to treat these cancers , which are part of a larger group of similar diseases called small cell neuroendocrine cancers .

1

2/22/2021

Partner

United States

Subscribe to see more

Subscribe to see more

10

5/12/2020

Partner

United States

Subscribe to see more

Subscribe to see more

10

Date

11/10/2021

5/25/2021

4/12/2021

2/22/2021

5/12/2020

Type

Vendor

Partner

Partner

Partner

Partner

Business Partner

Country

United States

United States

United States

United States

United States

News Snippet

Virpax Advances Envelta™ Development with NCATS Under CRADA Agreement

IND-enabling studies for Envelta are being performed under a Cooperative Research and Development Agreement with NCATS entered into by Virpax Pharmaceuticals in August of 2020 .

08:38 ET BurstIQ and The National Center for Advancing Translational Sciences (NCATS) At The National Institutes of Health (NIH)...

To learn more about BurstIQ 's collaboration with National Center for Advancing Translational Sciences and how the companies are working together to drive collaborative research , please contact us at -LSB- email protected -RSB- .

(Parth Desai, M.D., National Cancer Institute). National Center for Advancing Translational Sciences Drug Testing Approach Uncovers Effective Combination for Treating Small Cell Lung Cancer.

Scientists at NIH 's National Cancer Institute and NCATS teamed up to find another option to treat these cancers , which are part of a larger group of similar diseases called small cell neuroendocrine cancers .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

1

1

10

10

National Center For Advancing Translational Sciences Team

1 Team Member

National Center For Advancing Translational Sciences has 1 team member, including current Chief Medical Officer, Sam Bozzette MD PhD.

Name

Work History

Title

Status

Sam Bozzette MD PhD

Chief Medical Officer

Current

Name

Sam Bozzette MD PhD

Work History

Title

Chief Medical Officer

Status

Current

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.